Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers

被引:0
|
作者
Moura, Filipe A. [1 ,2 ]
Kamanu, Frederick K. [3 ]
Wiviott, Stephen D. [3 ]
Giugliano, Robert P. [3 ]
Udler, Miriam S. [4 ,5 ,6 ,7 ,8 ]
Florez, Jose C. [4 ,5 ,6 ,7 ,8 ]
Ellinor, Patrick T. [9 ,10 ]
Sabatine, Marc S. [3 ]
Ruff, Christian T. [3 ]
Marston, Nicholas A. [3 ]
机构
[1] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA
[2] VA Connecticut Healthcare Syst, West Haven, CT USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, Boston, MA USA
[4] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA USA
[5] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA USA
[6] Broad Inst Harvard & MIT, Programs Metab, Cambridge, MA USA
[7] Broad Inst Harvard & MIT, Programs Med & Populat Genet, Cambridge, MA USA
[8] Harvard Med Sch, Dept Med, Boston, MA USA
[9] Broad Inst MIT & Harvard, Cardiovasc Dis Initiat, Cambridge, MA USA
[10] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA USA
来源
DIABETES OBESITY & METABOLISM | 2025年 / 27卷 / 03期
基金
美国国家卫生研究院;
关键词
clinical trial; genetic epidemiology; genetic risk; incident diabetes; lipid-lowering therapy; PCSK9; inhibition; risk prediction; type; 2; diabetes; CARDIOVASCULAR-DISEASE; PCSK9; VARIANTS; MORTALITY;
D O I
10.1111/dom.16123
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To evaluate the predictive value of a contemporary type 2 diabetes (T2D) polygenic score (PGS) in detecting incident diabetes across a range of diabetes risk factors. Materials and Methods: We analysed participants in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial (, number NCT0176463), which compared the efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab versus placebo in lowering cardiovascular outcomes in participants with stable atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg/dL (1.8 mmol/L) or higher who were receiving statin therapy. Genetic risk was characterized using a previously validated T2D PGS based on similar to 1.2 million single-nucleotide polymorphisms. PGS was analysed continuously and categorically as high (top 20% of the PGS) and low to intermediate (lower 80% of the PGS). The effect of evolocumab on incident diabetes in patients without diabetes at baseline was also assessed. HbA1c was measured at baseline and every 24 weeks thereafter, while FPG was measured at baseline, week 12, week 24 and every 24 weeks thereafter. Potential cases of incident diabetes were adjudicated centrally. Hazards ratios (HRs) for incident diabetes were adjusted for baseline characteristics and ancestry. Results: Among 9388 participants, the mean age was 63 +/- 9 years and 22.7% were women, with median HbA1c 39 mmol/mol (36 mmol/mol - 41 mmol/mol; 5.7% [5.4%-5.9%]) and mean body mass index (BMI) 28.7 +/- 5 kg/m(2). Diabetes developed in 690 participants (7.3%) during 2.3 years of median follow-up. T2D PGS predicted incident T2D (HR per 1-SD 1.22, 95% CI 1.14-1.32, p < 0.001). The rates of incident T2D in the high and low to intermediate genetic risk categories were 12.1% versus 6.8%, respectively (HR 1.43 95% CI 1.20-1.70, p < 0.001). Notably, high T2D genetic risk had greater predictive strength among individuals with lower HbA1c (P-int = 0.0499) and lower BMI (P-int = 0.004). Conclusions: The T2D polygenic score serves as an independent predictor of incident diabetes, particularly among individuals with lower distribution of traditional risk factors.
引用
收藏
页码:1287 / 1295
页数:9
相关论文
共 50 条
  • [21] Dietary Sodium Intake and Risk of Incident Type 2 Diabetes
    Wang, Xuan
    Ma, Hao
    Kou, Minghao
    Tang, Rui
    Xue, Qiaochu
    Li, Xiang
    Harlan, Timothy S.
    Heianza, Yoriko
    Qi, Lu
    MAYO CLINIC PROCEEDINGS, 2023, 98 (11) : 1641 - 1652
  • [22] Vitamin D deficiency and the risk of incident Type 2 diabetes
    Michos, Erin D.
    FUTURE CARDIOLOGY, 2009, 5 (01) : 15 - 18
  • [23] Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
    Coleman, RL
    Stevens, RJ
    Holman, RR
    DIABETOLOGIA, 2005, 48 : A32 - A32
  • [24] Dietary Sodium Intake and Risk of Incident Type 2 Diabetes
    Wang, Xuan
    Ma, Hao
    Tang, Rui
    Xue, Qiaochu
    Li, Xiang
    Heianza, Yoriko
    Qi, Lu
    DIABETES, 2023, 72
  • [25] Risk of Incident Type 2 Diabetes According to Breakfast Habits
    Odegaard, Andrew
    Jacobs, David
    Steffen, Lyn
    Van Horn, Linda
    Ludwig, David
    Pereira, Mark
    DIABETES, 2012, 61 : A354 - A354
  • [26] Egg consumption and incident type 2 diabetes: A risk assessment
    Kawada, Tomoyuki
    CLINICAL NUTRITION, 2021, 40 (11) : 5417 - 5417
  • [27] Genetic Risk Score of Type 2 Diabetes and Progression Risk from Gestational Diabetes to Type 2 Diabetes: Results from Two Independent Populations
    Li, Mengying
    Rahman, Mohammad L.
    Wu, Jing
    Ding, Ming
    Chavarro, Jorge E.
    Lin, Yuan
    Ley, Sylvia H.
    Grunnet, Louise
    Hinkle, Stefanie
    Thuesen, Anne Cathrine Baun
    Yeung, Edwina
    Gore-Langton, Robert E.
    Sherman, Seth J.
    Hjort, Line
    Kampmann, Freja Bach
    Damm, Peter
    Tekola-Ayele, Fasil
    Liu, Aiyi
    Mills, James
    Vaag, Allan A.
    Esq, Sjurdur F. Olsen
    Hu, Frank
    Zhang, Cuilin
    DIABETES, 2019, 68
  • [28] A genetic risk score that includes common type 2 diabetes risk variants is associated with gestational diabetes
    Kawai, V. K.
    Levinson, R. T.
    Adefurin, A.
    Kurnik, D.
    Collier, S. P.
    Conway, D.
    Stein, C. M.
    CLINICAL ENDOCRINOLOGY, 2017, 87 (02) : 149 - 155
  • [29] Dietary Fat and the Genetic Risk of Type 2 Diabetes
    Germán D. Carrasquilla
    Hermina Jakupović
    Tuomas O. Kilpeläinen
    Current Diabetes Reports, 2019, 19
  • [30] Genetic Testing and Type 2 Diabetes Risk Awareness
    De Groot, Mary K.
    Wessel, Jennifer
    DIABETES, 2014, 63 : A198 - A198